Yasuhiro Fujisawa1, Shusuke Yoshikawa2, Akane Minagawa3, Tatsuya Takenouchi4, Kenji Yokota5, Hiroshi Uchi6, Naoki Noma7, Yasuhiro Nakamura8, Jun Asai9, Junji Kato10, Susumu Fujiwara11, Satoshi Fukushima12, Jiro Uehara13, Toshihiko Hoashi14, Tatsuya Kaji15, Taku Fujimura16, Kenjiro Namikawa17, Manabu Yoshioka18, Naoki Murata19, Dai Ogata20, Kanako Matsuyama21, Naohito Hatta22, Yoshitsugu Shibayama23, Toshiharu Fujiyama24, Masashi Ishikawa25, Daisuke Yamada26, Akiko Kishi27, Yoshiyuki Nakamura28, Takatoshi Shimiauchi29, Kazuyasu Fujii30, Manabu Fujimoto28, Hironobu Ihn31, Norito Katoh32. 1. Japanese Melanoma Study Group, Japan; Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, University of Tsukuba, Japan. Electronic address: fujisan@md.tsukuba.ac.jp. 2. Japanese Melanoma Study Group, Japan; Department of Dermatology, Shizuoka Cancer Center, Japan. 3. Japanese Melanoma Study Group, Japan; Department of Dermatology, Shinshu University School of Medicine, Japan. 4. Japanese Melanoma Study Group, Japan; Department of Dermatology, Niigata Cancer Center, Japan. 5. Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Nagoya, Japan. 6. Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Kyushu, Japan. 7. Japanese Melanoma Study Group, Japan; Department of Dermatology, Osaka City University, Japan. 8. Japanese Melanoma Study Group, Japan; Department of Dermatology, Saitama Medical University International Medical Center, Japan. 9. Japanese Melanoma Study Group, Japan; Department of Dermatology, Kyoto Prefectural University of Medicine, Japan. 10. Japanese Melanoma Study Group, Japan; Department of Dermatology, Sapporo Medical University, Japan. 11. Japanese Melanoma Study Group, Japan; Department of Dermatology, Kobe University, Japan. 12. Japanese Melanoma Study Group, Japan; Department of Department of Dermatology and Plastic Surgery, Kumamoto University, Japan. 13. Japanese Melanoma Study Group, Japan; Department of Dermatology, Asahikawa Medical University, Japan. 14. Japanese Melanoma Study Group, Japan; Department of Dermatology, Nippon Medical School, Japan. 15. Japanese Melanoma Study Group, Japan; Department of Dermatology, Okayama University Graduate School of Medicine, Japan. 16. Japanese Melanoma Study Group, Japan; Department of Dermatology, Tohoku University Graduate School of Medicine, Japan. 17. Japanese Melanoma Study Group, Japan; Department of Dermatologic Oncology, National Cancer Center Hospital, Japan. 18. Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Occupational Environment Health, Japan. 19. Japanese Melanoma Study Group, Japan; Department of Plastic Surgery, University of Hokkaido, Japan. 20. Japanese Melanoma Study Group, Japan; Department of Dermatology, Saitama Medical University, Japan. 21. Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Gifu, Japan. 22. Japanese Melanoma Study Group, Japan; Department of Dermatology, Toyama Prefectural Central Hospital, Japan. 23. Japanese Melanoma Study Group, Japan; Department of Dermatology, Fukuoka University, Japan. 24. Japanese Melanoma Study Group, Japan; Department of Dermatology, Hamamatsu University School of Medicine, Japan. 25. Japanese Melanoma Study Group, Japan; Department of Dermatology, Saitama Prefectural Cancer Center, Japan. 26. Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Tokyo, Japan. 27. Japanese Melanoma Study Group, Japan; Department of Dermatology, Toranomon Hospital, Japan. 28. Department of Dermatology, University of Tsukuba, Japan. 29. Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, Hamamatsu University School of Medicine, Japan. 30. Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, Kagoshima University, Japan. 31. Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Department of Dermatology and Plastic Surgery, Kumamoto University, Japan. 32. Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, Kyoto Prefectural University of Medicine, Japan.
Abstract
BACKGROUND: The American Joint Committee on Cancer (AJCC) 8th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. OBJECTIVE: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. METHODS: The AJCC 7th and 8th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8th staging were selected. The Kaplan-Meier method was used to estimate disease-specific survival and relapse-free survival. RESULTS: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7th and 8th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7th and 8th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA = 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID = none/6.5%. CONCLUSION: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7th and 8th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8th Edition staging were completely different from the 7th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively.
BACKGROUND: The American Joint Committee on Cancer (AJCC) 8th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. OBJECTIVE: The purpose of this study was to validate the new system using a cohort of Japanese melanomapatients. METHODS: The AJCC 7th and 8th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8th staging were selected. The Kaplan-Meier method was used to estimate disease-specific survival and relapse-free survival. RESULTS: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7th and 8th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7th and 8th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA = 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID = none/6.5%. CONCLUSION: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7th and 8th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8th Edition staging were completely different from the 7th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively.
Authors: Matthew C Hynes; Paul Nguyen; Patti A Groome; Yuka Asai; Meaghan E Mavor; Tara D Baetz; Timothy P Hanna Journal: BMC Cancer Date: 2022-07-01 Impact factor: 4.638